Highlights
– In a 13-site prospective cohort (ACTG A5381–Hakim) across six PEPFAR-supported countries, initiation or switching to tenofovir–lamivudine–dolutegravir (TLD) yielded high viral suppression for people suppressed at switch and for ART-naive individuals.
– Participants who switched from failing protease-inhibitor regimens (VL >1000 copies/mL) had lower suppression and were the only group with emergent dolutegravir-associated mutations (G118R, R263K) in three individuals.
